Literature DB >> 21550376

Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009.

P Tuppin1, S Samson, A Weill, P Ricordeau, H Allemand.   

Abstract

OBJECTIVES: To measure the seasonal influenza vaccination coverage rate (VCR) in France in 2009, year of the A(H1N1) influenza pandemic, by age and target disease and compare it with the VCR for the 2007 and 2008 influenza seasons.
METHOD: At the beginning of each annual seasonal vaccination campaign, the National Health Insurance, covering 86% of the French population, sends free influenza vaccination vouchers to at-risk beneficiaries aged under 65 suffering from diverse chronic diseases and to all individuals aged 65 and over (around 11 million). Vaccination is estimated from refund claims registered in the National Health Insurance Information System.
RESULTS: The global VCR for the target population was 51% in 2007, 55.8% in 2008 and 56.9% in 2009. In 2009, the VCR for children under 10 years old was 24.3%, 28.1% in the 10-19 age range, 39.2% in the 20-64 age range and 63.3% for individuals aged 65 and over, of which 72.3% with a targeted chronic disease and 56.9% without. The inclusion of asthma as a target disease, lowered the global VCR for children under 10 years old (30.6% without asthma) but VCR increased proportionally with the number of annual refunds for drugs against asthma and chronic obstructive pulmonary disease. The 2009 vaccine uptake rates in target group children, adolescents, young adults and to a lesser extent the population aged 65 and over suffering from a chronic disease (particularly chronic respiratory disease), could have been positively impacted by the A(H1N1) influenza context.
CONCLUSION: The influenza VCR varies considerably according to age and target disease but globally remains inferior to the recommended 75% coverage rate. These results permit the detailed analysis of VCR distribution by disease and target group and highlights areas for reflection and action. Specific studies should be conducted in order to understand why the VCR is lower in certain target groups.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550376     DOI: 10.1016/j.vaccine.2011.04.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Two-dose seasonal influenza vaccine coverage and timeliness among children aged 6 months through 3 years: An evidence from the 2010-11 to the 2014-15 seasons in Zhejiang province, east China.

Authors:  Yu Hu; Yaping Chen; Bing Zhang
Journal:  Hum Vaccin Immunother       Date:  2016-09-13       Impact factor: 3.452

2.  Field seasonal influenza vaccine effectiveness: evaluation of the screening method using different sources of data during the 2010/2011 French influenza season.

Authors:  Alessandra Falchi; Cecile Souty; Marie-Lise Grisoni; Anne Mosnier; Thomas Hanslik; Isabelle Daviaud; Laurent Varesi; Solen Kerneis; Fabrice Carrat; Thierry Blanchon
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

3.  Immunization against A/H1N1 pandemic flu (2009-2010) in pediatric patients at risk. What might be the most effective strategy? The experience of an health district of Northern Italy.

Authors:  Giuseppe Gregori; Fabio Faccini; Ermanno Bongiorni; Ilario Maffini; Roberto Sacchetti
Journal:  Ital J Pediatr       Date:  2012-05-17       Impact factor: 2.638

4.  School-based surveillance for influenza vaccine effectiveness during 2014-2015 seasons in Hong Kong.

Authors:  Ting F Leung; Renee W Y Chan; Angela Kwok; Wendy C S Ho; Mars K P Tao; Kam L Hon; Frankie W T Cheng; Albert M Li; Paul K S Chan
Journal:  Influenza Other Respir Viruses       Date:  2017-05-25       Impact factor: 4.380

5.  Rates of immunization against pandemic and seasonal influenza in persons at high risk of severe influenza illness: a cross-sectional study among patients of the French Sentinelles general practitioners.

Authors:  Ludivine Privileggio; Alessandra Falchi; Marie-Lise Grisoni; Cécile Souty; Clément Turbelin; Laure Fonteneau; Thomas Hanslik; Solen Kernéis
Journal:  BMC Public Health       Date:  2013-03-20       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.